Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease

References

• Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 28, 2022.
   Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. doi:10.1038/nrdp.2018.10
   PubMed Web of Science ®Google Scholar
• Leibovitch JN, Tambe AV, Cimpeanu E, et al. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope? Blood Rev. 2022;53:100925. doi:10.1016/j.blre.2021.100925
   PubMed Web of Science ®Google Scholar
• Williams DA, Esrick E. Investigational curative gene therapy approaches to sickle cell disease. Blood Adv. 2021;5(23):5452. doi:10.1182/bloodadvances.2021005567
   PubMed Web of Science ®Google Scholar
• United States Food & Drug Administration. FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years; 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years#:~:text=Action,older%20with%20sickle%20cell%20disease. Accessed May 19, 2022.
   Google Scholar
• Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017;8(3):321–326. doi:10.1021/acsmedchemlett.6b00491
   PubMed Web of Science ®Google Scholar
• Glaros AK, Razvi R, Shah N, Zaidi AU. Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol. 2021;12:20406207211001136. doi:10.1177/20406207211001136
   Web of Science ®Google Scholar
• Estepp JH, Kalpatthi R, Woods G, et al. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatr Blood Cancer. 2022;69(8):e29716. doi:10.1002/pbc.29716
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e333. doi:10.1016/s2352-3026(21)00059-4
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019;381(6):509–519. doi:10.1056/NEJMoa1903212
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Gordeuk VR, Telfer P, et al. Higher hemoglobin levels achieved with voxelotor are associated with lower vaso-occlusive crisis incidence: 72-week analysis from the HOPE study. Blood. 2020;136:31–32. doi:10.1182/blood-2020-140863
   Web of Science ®Google Scholar
• Minniti CP, Knight-Madden J, Tonda M, Gray S, Lehrer-Graiwer J, Biemond BJ. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease. Am J Hematol. 2021;96(4):E126–e128. doi:10.1002/ajh.26101
   PubMed Web of Science ®Google Scholar
• Shah N, Lipato T, Alvarez O, et al. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Rev Hematol. 2022;15(2):167–173. doi:10.1080/17474086.2022.2031967
   PubMed Web of Science ®Google Scholar
• Zaidi AU, Lipato T, Alvarez OA, et al. Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US. Blood. 2020;136:25. doi:10.1182/blood-2020-140525
   Web of Science ®Google Scholar
• Blyden G, Bridges KR, Bronte L. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access. Am J Hematol. 2018;93(8):E188–E190. doi:10.1002/ajh.25139
   Web of Science ®Google Scholar
• Muschick K, Fuqua T, Stoker-Postier C, Anderson AR. Real-World Data On Voxelotor To Treat Patients With Sickle Cell Disease. Eur J Haematol. 2022;109(2):154–161. doi:10.1111/ejh.13782
   PubMed Web of Science ®Google Scholar
• Nagalapuram V, Kanter J. Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease. Am J Hematol. 2022;97(8):E318–E320. doi:10.1002/ajh.26631
   PubMed Web of Science ®Google Scholar
• Vissa M, Vichinsky E. Voxelotor for the treatment of sickle cell disease. Expert Rev Hematol. 2021;14(3):253–262. doi:10.1080/17474086.2021.1893688
   PubMed Web of Science ®Google Scholar
• Phan V, Caldarera L, Cortez AL, et al. The Effect of Voxelotor on Exercise Capacity of Youths with Sickle Cell Anemia. Blood. 2021;138:2045. doi:10.1182/blood-2021-149163
   Web of Science ®Google Scholar
• Herity LB, Vaughan DM, Rodriguez LR, Lowe DK. Voxelotor: a Novel Treatment for Sickle Cell Disease. Ann Pharmacother. 2021;55(2):240–245. doi:10.1177/1060028020943059
   PubMed Web of Science ®Google Scholar
• Han J, Molokie RE, Hussain F, Njoku F, Gordeuk VR, Saraf SL. Voxelotor and albuminuria in adults with sickle cell anaemia. Br J Haematol. 2022;197(5). doi:10.1111/bjh.18076
   PubMed Web of Science ®Google Scholar
• Global Blood Therapuetics. Oxbryta [prescribing information]; 2022. Available from: https://www.oxbryta.com/taking-oxbryta. Accessed May 24, 2022.
   Google Scholar
• Han J, Saraf SL, Gordeuk VR. Systematic Review of Voxelotor: a First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. Pharmacotherapy. 2020;40(6):525–534. doi:10.1002/phar.2405
   PubMed Web of Science ®Google Scholar
• Rutherford-Parker NJ, Campbell ST, Colby JM. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes. Am J Clin Pathol. 2020;154(5):627–634. doi:10.1093/ajcp/aqaa067
   PubMed Web of Science ®Google Scholar
• Tsitsikas DA, Kamal M, Braimoh A, Benson S, Abukar J. Hb S (HBB: c.20A>T) Characteristics by High Performance Liquid Chromatography in Patients with Sickle Cell Disease Receiving the Novel Agent Voxelotor. Hemoglobin. 2021;45:1–3. doi:10.1080/03630269.2020.1788074
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Hedlund BE. Sickle hemoglobin oxygen affinity‐shifting strategies have unequal cerebrovascular risks. Am J Hematol. 2018;93(3):321–325. doi:10.1002/ajh.24975
   PubMed Web of Science ®Google Scholar
• Bradt P, Spackman E, Synnott P, et al. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. Ins Clin Economic Rev. 2020;1:58.
   Google Scholar
• Crosby LE, Walton A, Shook LM, et al. Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. J Pediatr Hematol Oncol. 2019;41(1):56–63. doi:10.1097/mph.0000000000001257
   PubMed Web of Science ®Google Scholar
• Wyatt KD, List B, Brinkman WB, et al. Shared Decision Making in Pediatrics: a Systematic Review and Meta-analysis. Acad Pediatr. 2015;15(6):573–583. doi:10.1016/j.acap.2015.03.011
   PubMed Web of Science ®Google Scholar
• Hood AM, Strong H, Nwankwo C, et al. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: protocol for a Multicenter Randomized Controlled Trial. JMIR Res Protoc. 2021;10(5):e27650. doi:10.2196/27650
   PubMed Web of Science ®Google Scholar
• Henry ER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood J Am Soc Hematol. 2021;138(13):1172–1181.
   Google Scholar